The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Visual abstract | PSOARING 3: 52-week safety and efficacy of tapinarof cream
The Psoriasis and Psoriatic Arthritis Hub is happy to present a visual abstract summarizing key findings from the phase III PSOARING 3 trial evaluating the long-term efficacy and safety of tapinarof 1% cream in patients with plaque psoriasis. Included patients had received 12 weeks of prior treatment with tapinarof or vehicle cream PSOARING 1 or 2 trials.
Overall, patients were enrolled for a total of 52 weeks (12 weeks in PSOARING 1 or 2, plus 40 weeks in PSOARING 3).1 In PSOARING 1 and 2, patients were randomly assigned 2:1 to tapinarof cream and vehicle.2 In PSOARING 3, patients received tapinarof until a PGA score of 0 was achieved and were monitored for remittive effect, with a total of 40.9% of patients achieved a PGA of 0 at least once during the trial.1
Results from the PSOARING 3 trial demonstrate the consistent safety profile and sustained efficacy of tapinarof cream at 52 weeks.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content